C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 6, 2000, Pages 621-630

  Yeun, Jane Y ^a,b   Kaysen, George A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BETAINE; C REACTIVE PROTEIN; CYANOCOBALAMIN; ENALAPRIL; FLUINDOSTATIN; FOLINIC ACID; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; LIPID; METHIONINE; PYRIDOXINE; SIMVASTATIN; TROPONIN I; TROPONIN T;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIET SUPPLEMENTATION; HEART MUSCLE INJURY; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; KIDNEY FAILURE; LIPID OXIDATION; METHYLATION; OXIDATIVE STRESS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; RENOVASCULAR DISEASE; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; HOMOCYSTEINE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; PROGNOSIS; TROPONIN;

EID: 0033693439     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200011000-00006     Document Type: Review

References (84)

1. Nontraditional cardiovascular risk factors
2. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
3. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
4. Inflammation, the acute phase response and atherosclerosis
5. C-Reactive protein and coronary artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndromes
6. Factors influencing serum albumin in dialysis patients
7. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia and mortality in hemodialysis patients
8. C-reactive protein as an outcome predictor for maintenance hemodialysis patients
9. Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients
10. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients
11. C-Reactive protein predicts allcause and cardiovascular mortality in hemodialysis patients
12. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
13. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients
14. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients
15. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients
16. Atherosclerosis - An inflammatory disease
17. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures
18. Intact human ceruloplasmin oxidatively modifies low density lipoprotein
19. C-reactive protein and atherosclerosis in dialysis patients
20. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
21. Inflammation and oxidative stress in chronic renal failure
22. An overview of haemodialysis and oxidant stress
23. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors
24. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients
25. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy
26. Higher levels of antioxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients
27. Analysis of 7-ketocholesterol in low density lipoprotein and fatty acid composition in erythrocyte membranes of patients on maintenance hemodialysis and healthy controls
28. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients
29. Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients
30. Leptin induces oxidative stress in human endothelial cells
31. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients
32. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients
33. Calcineurin inhibitors enhance low-density lipoprotein oxidation in transplant patients
34. Leptin and its clinical implications in chronic renal failure
35. Activation of 5-lipoxygenase and related cell membrane lipoperoxidation in hemodialysis patients
36. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy
37. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients
38. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients
39. Hemodialysis impairs endothelial function via oxidative stress: Effects of vitamin E-coated dialyzer
40. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients
41. Effect of simvastatin on the lipid profile of hemodialysis patients
42. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: Role of oxidative stress
43. The role of homocysteine in end-stage renal disease
44. Influence of 5,10-methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal disease
45. Evidence of altered homocysteine metabolism in chronic renal failure
46. Homocysteine and methionine metabolism in ESRD: A stable isotope study
47. Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients
48. Folio acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy
49. Carotid artery stiffness in patients with end-stage renal disease: No effect of long-term homocysteine-lowering therapy
50. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease
51. Treatment with different doses of folic acid in haemodialysis patients: Effects on folate distribution and aminothiol concentrations
52. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study
53. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients
54. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: Is homocyst(e)ine the missing link?
55. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients
56. Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients
57. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy
58. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis
59. Dialysis adequacy and homocyst(e)ine concentrations in peritoneal dialysis patients
60. Supplementation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease
61. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
62. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease
63. Prevalence, determinants, and clinical significance of hyperhomecyst(e)inaemia in renal-transplant recipients
64. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
65. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
66. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study
67. Plasma total homocysteine and hemodialysis access thrombosis: A prospective study
68. Homocysteine, B vitamins, and vascular-access thrombosis in patients treated with hemodialysis
69. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients
70. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
71. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: An effect reversible with vitamin C therapy
72. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: A randomised, placebo-controlled trial
73. Current markers of myocardial ischemia and their validity in end-stage renal disease
74. Improved troponin T ELISA specific for cardiac troponin T isoform: Assay development and analytical and clinical validation
75. Cardiac troponins in patients with renal dysfunction
76. Increased cardiac troponin T and endothelin-1 concentrations in dialysis patients may indicate heart disease
77. Cardiac troponin elevations in chronic renal failure: Prevalence and clinical significance
78. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: A 9-month outcome analysis
79. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: A pilot study
80. Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effect of hemodialysis on these cardiac markers
81. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis
82. Increased mortality in hemodialyzed patients with elevated serum troponin T: A one-year outcome study
83. Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim